Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Ovarian Research

Fig. 2

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 2

p53-Bad Fusion Construct. p53 both activates pro-apoptotic Bak and Bax as well as inactivates anti-apoptotic Bcl-W, Mcl-1, Bcl-2, and Bcl-xL [38]. Bad inactivates Bcl-W, Bcl-2, and Bcl-xL [39]. Thus, a fusion construct increases pro-apoptotic activity through dual inhibition of anti-apoptotic factors, as shown quantitatively previously by our lab (data unpublished, submitted for review)

Back to article page